SCG3 and retinopathy of prematurity: Recently, suppression of disordered retinal angiogenesis via supplementation of EPO and its derivatives, PUFAs, and IGF-1/IGFBP-3 complex, modulation of HIF, and inhibition of Scg3 has attracted the attention of researchers for the treatment of ROP.